JAK Inhibitor Compounds, Galderma Holding SA Patent

USPTO granted patent US12606559B2 to Galderma Holding SA covering novel JAK inhibitor compounds and methods of using them to treat diseases, conditions, and disorders. The patent's CPC classifications indicate applications in dermatology (A61P 17/00), pain (A61P 29/00), and oncology (A61P 35/00).

This patent grant confers exclusive intellectual property rights to Galderma Holding SA in the United States. Third parties seeking to manufacture, use, or sell compounds falling within the patent's claims may need to obtain a license or challenge the patent's validity. The filing date of March 8, 2023 establishes the priority date for the disclosed inventions.